A176750 Share Price Performance
₩6,070.00
-3950.00 (-39.42%)
39.3% undervalued intrinsic discount
₩10,000.00
Fair Value
Price ₩6,070.00
AnimalDoctorKwon ₩10,000.00
Fair Value₩10,000.00
Share Pricen/a
New Narrative • Jul 23
DuChemBIO Co.,Ltd. Stock Price
- 1 Narratives written by author
- 1 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
A176750 Community Narratives
AN
Fair Value
·Fair Value ₩10k 39.3% undervalued intrinsic discount
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
0users have liked this narrative
1users have commented on this narrative
1users have followed this narrative
DuChemBIOLtd
39.3% undervalued intrinsic discount
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
View narrativeAN
Published 23 Jul
Trending Discussion
Recently Updated Narratives
AN
DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.
Fair Value: ₩10k 39.3% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DuChemBIO Co.,Ltd. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- 240.57
- 37.81%
- 16.45%
- 11.4%
About A176750
- Founded
- 2002
- Employees
- 143
- CEO
- WebsiteView website
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.